-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Opinion|Videos|April 4, 2025

Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

Experts discuss how institutions can address the resource and bandwidth challenges that come with administering complex therapies like bispecifics.

Video content above is prompted by the following:

How can institutions address the resource and bandwidth challenges that come with administering complex therapies like bispecifics?


Related to this article

Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.